Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

The stock's fall snapped a four-day winning streak.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

When asked today if Ireland will follow such a move, the health minister said Mounjaro, “is going through the reimbursement ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast ...

Evangeline Lilly has cancelled an appearance at the Italian Global Series Festival (IGSF) for health reasons. The star, who ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn.

In Q4 2024, worldwide revenue was $13.53 billion, an increase of 45% compared with Q4 2023, driven by a 48% increase in volume, partially offset by a 4% decrease due to lower realized prices.